Overall, SETD2 wt/H3K36me3-positive tumor regions showed more epigenetic and genetic level ITH, suggesting that SETD2 mutations drive an epigenetic landscape that promotes a distinct and more homogeneous epigenome associated with adverse outcomes. This evidence concerns the gene SETD2 and neoplasm.